廣告
香港股市 已收市

  • 恒指

    16,224.14
    -161.73 (-0.99%)
     

  • 國指

    5,746.61
    -57.25 (-0.99%)
     

  • 上證綜指

    3,065.26
    -8.96 (-0.29%)
     

  • 滬深300

    3,541.66
    -28.14 (-0.79%)
     

  • 美元

    7.8333
    +0.0021 (+0.03%)
     

  • 人民幣

    0.9238
    +0.0001 (+0.01%)
     

  • 道指

    37,775.38
    +22.07 (+0.06%)
     

  • 標普 500

    5,011.12
    -11.09 (-0.22%)
     

  • 納指

    15,601.50
    -81.87 (-0.52%)
     

  • 日圓

    0.0504
    +0.0000 (+0.06%)
     

  • 歐元

    8.3524
    +0.0180 (+0.22%)
     

  • 英鎊

    9.7490
    +0.0100 (+0.10%)
     

  • 紐約期油

    82.21
    -0.52 (-0.63%)
     

  • 金價

    2,393.10
    -4.90 (-0.20%)
     

  • Bitcoin

    64,666.86
    +2,485.27 (+4.00%)
     

  • CMC Crypto 200

    1,337.50
    +24.87 (+1.93%)
     

Evolent Expands Its Portfolio For Musculoskeletal Conditions With This Deal

Vandana Singh
更新日期： ·1 分鐘文章

  • Evolent Health Inc has agreed to acquire IPG, a technology and services company providing surgical management solutions for musculoskeletal conditions, from TPG Growth.

  • The deal value includes $375 million plus additional consideration of up to $87 million. It is expected to close in Q3 of 2022.

  • Upon close, the IPG team and platform will be integrated into New Century Health.

  • The deal expands Evolent's specialty focus to include surgical cost management focusing on musculoskeletal conditions, adding to its specialty portfolio of oncology, cardiology, and end-of-life care planning.

  • Evolent Health expects the transaction to be immediately accretive to adjusted EBITDA margins and cash flow.

  • It expects meaningful revenue cross-sell synergy opportunity with health plan and risk-bearing provider customers.

  • For 2022, IPG standalone revenues are expected to be $140 million, with an adjusted EBITDA of $25 million (approximately 18% margin) and annual sales growth of over 20%.

  • Evolent will fund $250 million of the purchase price in cash through a combination of $25 million cash on hand and proceeds from a new $225 million Five Year Senior Credit Facility provided by Ares Management.

  • Evolent ended the March quarter with a cash balance of $210.2 million.

  • Price Action: EVH shares closed at $30.88 on Tuesday.

View more earnings on EVH

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.